In the Margins

Sequoia Fund's Valeant bet highlights concentration risks

November 2, 2015

By The Wall Street Journal

Concentrated bets on individual stocks raise issues for mutual funds and their investors—a matter highlighted last week at Sequoia Fund, one of the biggest investors in controversial drug maker Valeant Pharmaceuticals International Inc. Placing outsize bets on well-chosen stocks can lead to strong performance, but concentration increases the riskiness of a fund and raises questions about how much is too much. Read the original story from The Wall Street Journal.

 

 

Most Read

A Seat at the Table
Invesco Funds board finalizes succession plans

The Invesco Funds board will name Christopher Wilson vice chairman at its June meeting, making him the heir apparent to long-serving independent Chair Bruce Crockett. Crockett ...

Top of the Agenda - Compensation
Fund board comp moves up, as industry keeps changing

Analyzing mutual fund director compensation data is getting increasingly difficult as consolidation reshapes the mid-sized to large end of the market and a reduction in stand-alone ...

Top of the Agenda - Industry Groups
IDC's Amy Lancellotta to retire at year-end

Amy Lancellotta will retire from the Independent Directors Council at the end of this year after 13 years as managing director and a total of 30 ...